[go: up one dir, main page]

EA201790958A1 - Сублингвальный препарат рилузола - Google Patents

Сублингвальный препарат рилузола

Info

Publication number
EA201790958A1
EA201790958A1 EA201790958A EA201790958A EA201790958A1 EA 201790958 A1 EA201790958 A1 EA 201790958A1 EA 201790958 A EA201790958 A EA 201790958A EA 201790958 A EA201790958 A EA 201790958A EA 201790958 A1 EA201790958 A1 EA 201790958A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rilusol
sublingual
riluzole
sublingual preparation
preparation
Prior art date
Application number
EA201790958A
Other languages
English (en)
Other versions
EA038518B1 (ru
Inventor
Владимир Корик
Роберт М. Берман
Рональд Сэмюэл Владыка
Амгад Салех
Дэнни Ю
Original Assignee
Биохэйвен Фармасьютикал Холдинг Компани Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохэйвен Фармасьютикал Холдинг Компани Лтд. filed Critical Биохэйвен Фармасьютикал Холдинг Компани Лтд.
Publication of EA201790958A1 publication Critical patent/EA201790958A1/ru
Publication of EA038518B1 publication Critical patent/EA038518B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Раскрыто сублингвальное введение рилузола. В частности, настоящее изобретение относится к способу лечения психоневрологического расстройства или симптома с помощью введения сублингвального препарата рилузола. Кроме того, раскрыт способ облегчения или уменьшения боли в ротовой полости с помощью сублингвального препарата рилузола.
EA201790958A 2014-11-21 2015-11-17 Сублингвальный препарат рилузола EA038518B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083094P 2014-11-21 2014-11-21
PCT/US2015/061114 WO2016081472A1 (en) 2014-11-21 2015-11-17 Sublingual formulation of riluzole

Publications (2)

Publication Number Publication Date
EA201790958A1 true EA201790958A1 (ru) 2018-01-31
EA038518B1 EA038518B1 (ru) 2021-09-09

Family

ID=55085882

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790958A EA038518B1 (ru) 2014-11-21 2015-11-17 Сублингвальный препарат рилузола

Country Status (24)

Country Link
US (3) US11660267B2 (ru)
EP (3) EP3220891B1 (ru)
JP (3) JP6753860B2 (ru)
KR (2) KR102811263B1 (ru)
CN (1) CN107249567B (ru)
AU (2) AU2015350148B2 (ru)
BR (1) BR112017010423B1 (ru)
CA (1) CA2967662A1 (ru)
CY (1) CY1122469T1 (ru)
DK (1) DK3220891T3 (ru)
EA (1) EA038518B1 (ru)
ES (2) ES2882783T3 (ru)
HR (1) HRP20191892T8 (ru)
HU (1) HUE046869T2 (ru)
IL (2) IL278188B2 (ru)
LT (1) LT3220891T (ru)
MX (1) MX368838B (ru)
PH (1) PH12017500934B1 (ru)
PL (1) PL3220891T3 (ru)
PT (1) PT3220891T (ru)
RS (1) RS59490B1 (ru)
SG (1) SG11201703896QA (ru)
SI (1) SI3220891T1 (ru)
WO (1) WO2016081472A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
CN112203692A (zh) * 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
AU2019322889A1 (en) * 2018-08-16 2021-03-04 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
WO2021081108A1 (en) * 2019-10-22 2021-04-29 Arvinas Operations, Inc. Methods of treating prostate cancer
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
CA3193824A1 (en) * 2020-10-05 2022-04-14 Ana PEREIRA Riluzole for the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113876735B (zh) * 2021-10-20 2023-05-12 陇南市第一人民医院 一种利鲁唑微球制剂及其制备方法
KR102625977B1 (ko) 2021-11-24 2024-01-17 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
AU691195B2 (en) 1993-07-09 1998-05-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
AU724947B2 (en) * 1996-12-20 2000-10-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Method of increasing the sweetening power and enhancing the taste of a mixture of high-intensity sweeteners
CA2281473C (en) 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
AU8977698A (en) 1997-07-25 1999-02-16 Elan Corporation, Plc A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
EE05190B1 (et) 1998-11-20 2009-08-17 Rtp Pharma Inc. Dispergeeruvad fosfolipiididega stabiliseeritud mikroosakesed
DE69923998T2 (de) * 1998-12-09 2006-04-27 Chiron Corp., Emeryville Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6432992B1 (en) * 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6908626B2 (en) 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
CN1649614A (zh) * 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
WO2004105756A2 (en) * 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
JP5269894B2 (ja) 2007-06-27 2013-08-21 ハンミ ファーム． シーオー．， エルティーディー． 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
WO2010009279A1 (en) * 2008-07-15 2010-01-21 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating alzheimer's disease
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
WO2010096869A1 (en) * 2009-02-26 2010-09-02 Steven Michael Weiss An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
RS53227B (en) * 2011-03-01 2014-08-29 Pharnext THERAPY OF NEUROLOGICAL DISORDERS BY COMBINATION OF Baclofen AND ACAMPROSAT
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
AU2012281042B2 (en) * 2011-07-13 2016-07-14 Cytokinetics, Inc. Combination ALS therapy
CA2864008C (en) * 2012-03-01 2020-04-21 Pharnext New compositions for treating amyotrophic lateral sclerosis
WO2016081466A1 (en) 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
SG10201908354VA (en) * 2015-03-03 2019-10-30 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use

Also Published As

Publication number Publication date
LT3220891T (lt) 2019-11-11
MX2017006446A (es) 2018-02-12
AU2021201034A1 (en) 2021-03-11
JP2023065398A (ja) 2023-05-12
PH12017500934A1 (en) 2017-11-20
US12121609B2 (en) 2024-10-22
ES2751300T3 (es) 2020-03-31
CN107249567B (zh) 2021-08-03
IL252285A0 (en) 2017-07-31
HRP20191892T8 (hr) 2020-09-18
EA038518B1 (ru) 2021-09-09
KR102811263B1 (ko) 2025-05-23
KR20230135183A (ko) 2023-09-22
US11660267B2 (en) 2023-05-30
MX368838B (es) 2019-10-18
EP3220891A1 (en) 2017-09-27
IL278188B2 (en) 2025-03-01
RS59490B1 (sr) 2019-12-31
AU2015350148B2 (en) 2020-11-26
AU2021201034B2 (en) 2023-07-06
DK3220891T3 (da) 2019-11-04
US20180153794A1 (en) 2018-06-07
CN107249567A (zh) 2017-10-13
HUE046869T2 (hu) 2020-04-28
EP4039247A2 (en) 2022-08-10
JP2021001173A (ja) 2021-01-07
KR102580378B1 (ko) 2023-09-19
SG11201703896QA (en) 2017-06-29
IL252285B (en) 2020-10-29
EP3220891B1 (en) 2019-07-24
SI3220891T1 (sl) 2020-02-28
HRP20191892T1 (hr) 2020-01-10
PL3220891T3 (pl) 2020-08-24
EP3616686B8 (en) 2021-06-23
BR112017010423B1 (pt) 2023-09-26
CY1122469T1 (el) 2021-01-27
WO2016081472A1 (en) 2016-05-26
US20250114301A1 (en) 2025-04-10
EP3616686A1 (en) 2020-03-04
PH12017500934B1 (en) 2024-06-28
ES2882783T3 (es) 2021-12-02
US20210038499A1 (en) 2021-02-11
BR112017010423A2 (pt) 2017-12-26
CA2967662A1 (en) 2016-05-26
KR20170137032A (ko) 2017-12-12
AU2015350148A1 (en) 2017-06-15
EP3616686B1 (en) 2021-05-19
IL278188B1 (en) 2024-11-01
JP2017535613A (ja) 2017-11-30
IL278188A (en) 2020-11-30
PT3220891T (pt) 2019-10-31
EP4039247A3 (en) 2022-11-16
JP6753860B2 (ja) 2020-09-09

Similar Documents

Publication Publication Date Title
EA201790958A1 (ru) Сублингвальный препарат рилузола
EA201791110A1 (ru) Сублингвальное введение рилузола
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
IN2014CH00247A (ru)
PH12017501035A1 (en) Method for the production of a pharmaceutical delivery system
PH12017500747B1 (en) Heterocyclic compound
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX376782B (es) Métodos de administración de composiciones de amantadina.
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
MX382608B (es) Tratamiento del prurito urémico.
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
IN2014CH01391A (ru)
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
UA96409U (uk) Спосіб реабілітації жінок після перенесеного сальпінгоофориту
IN2014DE00822A (ru)
IN2014CH00671A (ru)
IN2014DE00818A (ru)